Correction: Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response
نویسندگان
چکیده
Correction for ‘Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response’ Jie Yu et al. , Nanoscale 2021, DOI: 10.1039/d1nr03288g.
منابع مشابه
Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death
Immunotherapeutic approaches to manage patients with advanced gastrointestinal malignancies are desired; however, mechanisms to incite tumor-specific immune responses remain to be elucidated. Rose bengal (RB) is toxic at low concentrations to malignant cells and may induce damage-associated molecular patterns; therefore, we investigated its potential as an immunomodulator in colon cancer. Murin...
متن کاملMAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
Pharmacological inhibition of the MAPK pathway with MEK or BRAF antagonists has proved successful in inducing regression of melanoma tumors bearing the targeted activating mutations. Moreover, antibodies targeting T-cell immune checkpoint inhibitors CTLA-4 or PD-L1/PD-1 have demonstrated the capacity to generate durable responses in patients with multiple cancer types. Thus, combining MAPK path...
متن کاملCell-specific PD-L1 expression in DLBCL.
In this issue of Blood, a new study by Kiyasu et al used a double-staining technique to identify cell-specific programmed cell death ligand 1 (PD-L1) expression in 1253 diffuse large B-cell lymphoma (DLBCL) samples and analyzed the findings together with programmed death-1 (PD-1) expression in tumorinfiltrating lymphocytes (TILs) and clinical outcomes, providing new insights into the role of th...
متن کاملMelanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Anti-PD-1 therapy yields objective clinical responses in 30-40% of advanced melanoma patients. Since most patients do not respond, predictive biomarkers to guide treatment selection are needed. We hypothesize that MHC-I/II expression is required for tumour antigen presentation and may predict anti-PD-1 therapy response. In this study, across 60 melanoma cell lines, we find bimodal expression pa...
متن کاملImmunogenic cell death in radiation therapy
Radiation therapy has been extensively employed throughout the last century to treat individuals affected by multiple types of tumors, with a variable degree of success. Current estimates indicate indeed that at least 50% of cancer patients all confounded have been or will be exposed to ionizing irradiation, either as a standalone intervention or combined with chemoand/or immunotherapeutic regi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nanoscale
سال: 2021
ISSN: ['2040-3372', '2040-3364']
DOI: https://doi.org/10.1039/d1nr90174e